NCPA scholarship recipients announced
NEW ORLEANS The National Community Pharmacists Association Foundation announced recipients of scholarships for the 2009-2010 academic year Monday.
The foundation announced the recipients the NCPA’s 111th annual convention and trade exposition in New Orleans, which began Saturday and will continue until Wednesday.
“The NCPA Foundation is pleased to recognize and support this year’s student achievers,” NCPA Foundation president Sharlea Leatherwood said in a statement. “The future of community pharmacy is truly in capable hands with the leadership all of the award winners have shown.”
University of Kansas student Neil Young was named 2009 recipient of the Willard B. Simmons Sr. Memorial Scholarship, which the foundation gives to a student who has demonstrated interest in pharmacy management.
Washington State University student Andrew Helm received the J.C. and Rheba Cobb Memorial Scholarship, given to students who show interest in civic and government affairs.
University of Arizona student Lauren Bartoli received the Neil Pruitt Sr. Memorial Scholarship, given based on leadership, academic achievement and interest in entrepreneurism.
The organization also gave its 2009 Presidential Scholarships to 18 students, selected on the basis of academic achievement, leadership, interest in community pharmacy and extracurricular accomplishments. The recipients are:
- Richard Boyd, Ohio Northern University
- Whitney Brace, University of Texas at Austin
- Manpreet Chahal, Washington State University
- Getrude Chimhungwe, University of Buffalo
- Jinal Desai, University of Southern Nevada-South Jordan
- Stephanie Field, West Virginia University
- Paul Frazier, University of Southern Nevada-South Jordan
- Scott Halvorson, University of Missouri-Kansas City
- Tanaz Kohan, University of Southern California
- Lauren Marston, Virginia Commonwealth University
- Chibuzor Okoro, Howard University
- Brittany Provence, Drake University
- Summer Schroeder, University of New Mexico
- Regina Scott, University of New Mexico
- Cassandra Shields, University of Missouri-Kansas City
- Renee Tobey, University of Oklahoma Health Science Center
- Kendra VanGrinsven, University of Wyoming
- Hillary Volsteadt, Mercer University
A further seven Partners in Pharmacy Scholarships went to students who had demonstrated academic achievement, community service and interest in independent community pharmacy. The recipients of those scholarships are:
- Lucas Bozick, Texas Tech Health Science Center
- Jennifer Evans, University of Southern Nevada-South Jordan
- Sarah Griffin, University of Arkansas
- Julie Keeton, University of Kansas
- Staci Kurmel, Incarnate Word Feik School of Pharmacy
- Jennifer Nemnich, University of Kansas
- Thurston, Washington State University
Sandoz launches two products
PRINCETON, N.J. The generics arm of drug maker Novartis has launched two new products.
Sandoz announced the launch of topiramate sprinkle capsules, a generic version of Johnson & Johnson’s epilepsy drug Topamax Sprinkle, and calcium acetate capsules, an authorized generic of Fresenius Medical Care’s kidney failure drug PhosLo.
Topiramate capsules had sales of $56 million during the 12-month period ending in August, and PhosLo had sales of $42 million during the same period, according to IMS Health data.
FDA approves GSK’s HPV vaccine
PHILADELPHIA Merck & Co.’s highly successful human papillomavirus vaccine Gardasil has a new competitor.
The Food and Drug Administration approved GlaxoSmithKline’s Cervarix (human papillomavirus bivalent [types 16 and 18] vaccine, recombinant), for preventing infection by HPV – the virus that causes genital warts and can cause cervical cancer – in girls and women ages 10 to 25.
“The approval of Cervarix will bring an important new cervical cancer vaccine to girls and young women,” GSK president North American pharmaceuticals Deirdre Connelly said in a statement. “Immunization with a vaccine such as Cervarix – along with annual doctor visits and Pap tests – will help protect women from cervical cancer, the second leading cause of cancer death in women in their 20s and 30s.”
The FDA has already approved Merck’s Gardasil (human papillomavirus quadrivalent [types 6, 11, 16 and 18] vaccine, recombinant) for females and males ages 9 to 26.